Navigation Links
Ibrutinib Monotherapy Clinical Trial Data in Patients with Waldenstrom's Macroglobulinemia Presented at the International Conference on Malignant Lymphoma in Lugano, Switzerland
Date:6/20/2013

lity and terms of any such financing, the safety and/or efficacy results of clinical trials of our product candidates, our failure to obtain regulatory approvals or comply with ongoing governmental regulation, our ability to commercialize, manufacture and achieve market acceptance of any of our product candidates, for which we rely heavily on collaboration with third parties, and our ability to protect and enforce our intellectual property rights and to operate without infringing upon the proprietary rights of third parties. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, performance or achievements and no assurance can be given that the actual results will be consistent with these forward-looking statements. For more information about the risks and uncertainties that may affect our results, please see the Risk Factors section of our filings with the Securities and Exchange Commission, including our transition report on Form 10-K for the six month period ended December 31, 2012 and quarterly reports on Form 10-Q. We do not intend to update any of the forward-looking statements after the date of this announcement to conform these statements to actual results, to changes in management's expectations or otherwise, except as may be required by law.

References

[1] Pub Med Health. Waldenstrom's macroglobulinemia; macroglobulinemia - primary; Lymphoplasmacytic lymphoma. Available from: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001614/. Accessed May 14, 2013.

[2] American Cancer Society. Waldenstrom macroglobulinema. Available from: http://www.cancer.org/acs/groups/cid/documents/webcontent/003148-pdf.pdf. Accessed May 14, 2013.

[3] Garcia-Sanz R, Ocio E. Novel treatment regimens for Waldenstrom's
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Ibrutinib Phase 2 Study Results in Patients with Mantle Cell Lymphoma Published in The New England Journal of Medicine
2. Ibrutinib Study Results in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Published in The New England Journal of Medicine
3. Updated Results of Two Phase 2 Ibrutinib Studies in Patients with Mantle Cell Lymphoma or Diffuse Large B-cell Lymphoma
4. Ibrutinib Phase 2 Data: Analyses Show Efficacy with Ibrutinib Monotherapy in Patients with Relapsed or Refractory Mantle Cell or Diffuse Large B-cell Lymphoma
5. Ibrutinib Expanded Access Program Open to Eligible U.S. Patients with Relapsed or Refractory Mantle Cell Lymphoma
6. Phase II Ibrutinib Monotherapy Study Shows CLL Patients Achieved Rapid and Sustainable Disease Control Irrespective of Age or High Risk Prognostic Factor
7. Pharmacyclics Announces Third Breakthrough Therapy Designation for Ibrutinib from the U.S. Food and Drug Administration
8. Ibrutinib Receives Two Oncology Breakthrough Therapy Designations from U.S. Food and Drug Administration
9. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, in Relapsed/Refractory Mantle Cell Lymphoma Presented at American Society of Hematology Annual Meeting
10. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, Suggest High and Durable Responses in Relapsed/Refractory Mantle Cell Lymphoma
11. Pharmacyclics Announces Oral Presentations of Ibrutinib (PCI-32765) at the 17th Congress of the European Hematology Association
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... 30, 2014 Aileron Therapeutics, Inc. - ... Global Markets Direct,s, ,Aileron Therapeutics, Inc. - Product ... the Aileron Therapeutics, Inc.,s pharmaceutical research and development ... the current therapeutic developmental pipeline of Aileron Therapeutics, ... therapeutics assessment by drug target, mechanism of action ...
(Date:9/30/2014)... ATLANTA , Sept. 30, 2014  Alimera Sciences, ... company that specializes in the research, development and commercialization ... received a $25 million advance from Hercules Technology Growth ... payment is the second and final advance under the ... United Kingdom , Alimera Sciences Limited, ...
(Date:9/30/2014)... , N.J. and NEW BRUNSWICK, N.J., Sept. 30, 2014 ... agreement that allows Kessler Foundation and New Jersey ... biomedical research, education and patient care programs has ... and chief executive officer of Kessler Foundation and ... Jersey Health Foundation. "The experience of ...
Breaking Medicine Technology:Aileron Therapeutics, Inc. - Product Pipeline Review - 2014 2Aileron Therapeutics, Inc. - Product Pipeline Review - 2014 3Alimera Sciences Receives $25 Million Advance from Hercules Technology Growth Capital 2Kessler Foundation Partners with New Jersey Health Foundation To Start Innovative Companies To Change the Lives of People with Disabilities 2
... JERUSALEM, October 20 Oramed Pharmaceuticals,Inc. (OTCBB: ORMP.OB; ... today that its poster entitled "A novel GLP-1,analog delivered ... been accepted for presentation at the Diabetes Technology,Society,s Ninth ... , "The selection of Oramed ...
... Oct. 20 Aethlon Medical, Inc. (OTC Bulletin Board: ... Aethlon Hemopurifier® is effective in capturing the current pandemic ... is the first-in-class medical device able to selectively remove ... During invitro studies, the Hemopurifier® removed 68% ...
Cached Medicine Technology:Oramed Pharmaceuticals was Chosen to Present Results of a GLP-1 Analog Oral Administration Study at the Diabetes Technology Society's Ninth Annual Meeting (November 5-7, 2009; San Francisco, CA) 2Aethlon Medical Releases Medical Device Data Against the H1N1 Swine Flu Virus 2Aethlon Medical Releases Medical Device Data Against the H1N1 Swine Flu Virus 3
(Date:9/30/2014)... Legislation passed in 2003 to slow the spiraling ... to treat Medicare patients has had no meaningful impact ... researchers in the Journal of Clinical Oncology ... outpatient chemotherapy to treat colorectal and lung cancers, and ... prescribe those drugs following the implementation of the recent ...
(Date:9/30/2014)... 30, 2014 Research by UC Irvine immunologists reveals ... light on a vital process that determines how the ... online version of Nature Immunology , neurology professor ... Institute for Immunology colleagues describe a critical mechanism underlying ... the bloodstream. , A T cell is a type ...
(Date:9/30/2014)... 30, 2014 Fat Burning Kitchen , ... best-selling author Mike Geary that is helping people learn the ... into a fat-burning machine in less than 24 hours has ... , “In our culture that is becoming so obsessed ... decipher what is really fact and fiction when it comes ...
(Date:9/30/2014)... White Plains, NY (PRWEB) September 30, 2014 ... (HPCW) recently hosted its annual “In Celebration” gala, ... furthering the nonprofit’s mission of striving to provide ... individuals and families facing a serious or life-limiting ... Westchester Country Club in Rye, NY and recognized ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 Two revolutionary procedures ... treatment of gum disease a far less painful ... past. , “If you’ve ever felt electric shock waves surge ... sip a cold beverage, it’s possible you already know the ... who is a general dentist in West Palm Beach, and ...
Breaking Medicine News(10 mins):Health News:Landmark Medicare law had little impact on reducing chemotherapy cost 2Health News:UCI study uncovers important process for immune system development 2Health News:Fat Burning Kitchen: Review Exposes Mike Geary’s 24-Hour Diet Transformation for Helping the Body Burn Fat Through a Natural Diet 2Health News:Fat Burning Kitchen: Review Exposes Mike Geary’s 24-Hour Diet Transformation for Helping the Body Burn Fat Through a Natural Diet 3Health News:Hospice & Palliative Care of Westchester Honors Outstanding Individuals at Annual ‘In Celebration’ Gala 2Health News:Florida Dentist Battles Gum Disease With Latest Techniques 2Health News:Florida Dentist Battles Gum Disease With Latest Techniques 3
... PHILADELPHIA, May 15 The Mobile Massage Team ( ... services for corporate wellness programs, promotional events, and special affairs, ... the 7th Annual Yoga Unites(R) for Living Beyond Breast Cancer ... May 17, from 8:00 a.m. to 12:00 p.m. on the ...
... Paul Capital Healthcare today announced that New York-based partner, ... forms of financing at the 2009 BIO International Convention. ... non-dilutive financing options that can meet the needs of ... and Other Non-traditional Forms of Financing," is scheduled for ...
... PTN ) announced today results for its third quarter ... million, or $0.00 per basic and diluted share, for the quarter ... million, or $0.06 per basic and diluted share, for the same ... 31, 2009 were $5.2 million, compared to $0.7 million for the ...
... Researchers at Intermountain Medical Center in Salt Lake City ... atrial fibrillation, a fairly common heart rhythm disorder, and ... , In a study presented Friday, May 15, at ... Heart Rhythm Society in Boston, researchers unveiled findings from ...
... (NYSE Amex:, SVA ), a leading developer and provider of vaccines ... March 31, 2009. , , Recent Highlights, ... sole provider of, approximately $12.8 million ... inactivated hepatitis A vaccine, Healive, to China,s Ministry of Public, ...
... - U.S. and international thought leaders featured -SAN FRANCISCO, ... trusted resource for clinical trial management systems, this week ... institutions and industry partners at its annual meeting in ... to discuss a variety of initiatives and to hear ...
Cached Medicine News:Health News:Paul Capital Healthcare to Participate in Panel on Non-Traditional Forms of Financing 2Health News:Palatin Technologies, Inc. Reports Fiscal Year 2009 Third Quarter Results; Teleconference and Webcast to be held on May 15, 2009 2Health News:Palatin Technologies, Inc. Reports Fiscal Year 2009 Third Quarter Results; Teleconference and Webcast to be held on May 15, 2009 3Health News:Palatin Technologies, Inc. Reports Fiscal Year 2009 Third Quarter Results; Teleconference and Webcast to be held on May 15, 2009 4Health News:Palatin Technologies, Inc. Reports Fiscal Year 2009 Third Quarter Results; Teleconference and Webcast to be held on May 15, 2009 5Health News:Palatin Technologies, Inc. Reports Fiscal Year 2009 Third Quarter Results; Teleconference and Webcast to be held on May 15, 2009 6Health News:Study makes first connection between heart disorder and Alzheimer's disease 2Health News:Sinovac Reports Unaudited First Quarter 2009 Financial Results 2Health News:Sinovac Reports Unaudited First Quarter 2009 Financial Results 3Health News:Sinovac Reports Unaudited First Quarter 2009 Financial Results 4Health News:Sinovac Reports Unaudited First Quarter 2009 Financial Results 5Health News:Sinovac Reports Unaudited First Quarter 2009 Financial Results 6Health News:Sinovac Reports Unaudited First Quarter 2009 Financial Results 7Health News:Sinovac Reports Unaudited First Quarter 2009 Financial Results 8Health News:Sinovac Reports Unaudited First Quarter 2009 Financial Results 9Health News:Sinovac Reports Unaudited First Quarter 2009 Financial Results 10Health News:Sinovac Reports Unaudited First Quarter 2009 Financial Results 11Health News:Sinovac Reports Unaudited First Quarter 2009 Financial Results 12Health News:Sinovac Reports Unaudited First Quarter 2009 Financial Results 13Health News:Top Academic Medical Centers, Research Institutions, Partners Gather, Share Experiences, Success Stories at Velos Annual Meeting 2Health News:Top Academic Medical Centers, Research Institutions, Partners Gather, Share Experiences, Success Stories at Velos Annual Meeting 3
...
...
Bimod, acetabular cup "Xl" UHMWHDPE....
Metal on metal hip acetabular cups available for both cemented and cementless applications, the Biomet Merck metal on metal articulation hip system (M2aTM) combines proven materials with the latest i...
Medicine Products: